Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

被引：31
|
作者：
Kim, Gene H. [1 ,2 ]
Levy, Alan [3 ]
Compoginis, Goli [1 ,3 ]
机构：
[1] Univ So Calif, Dept Dermatol, Los Angeles, CA USA
[2] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA
[3] Levy Dermatol, Memphis, TN USA
来源：
JOURNAL OF CUTANEOUS PATHOLOGY | 2013年 / 40卷 / 07期
关键词：
drug reaction; melanoma; panniculitis; vemurafenib; BRAF; GENETICS;
D O I：
10.1111/cup.12149
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.
引用
收藏
页码：667 / 669
页数：3
相关论文
共 50 条
  • [41] Advances in the treatment of metastatic melanoma
    Matikas, A.
    Mavroudis, D.
    ARCHIVES OF HELLENIC MEDICINE, 2015, 32 (01): : 28 - 35
  • [42] Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma
    Yilmaz, Mesut
    Mese, Sermin Guven
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1754 - 1758
  • [43] Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury
    Teuma, Cecile
    Pelletier, Solenne
    Amini-Adl, Mona
    Perier-Muzet, Marie
    Maucort-Boulch, Delphine
    Thomas, Luc
    Laville, Maurice
    Fouque, Denis
    Dalle, Stephane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 1043 - 1049
  • [44] Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
    del Carmen Alamo, Ma
    Ochenduszko, Sebastian
    Crespo, Guillermo
    Corral, Monica
    Oramas, Juana
    Sancho, Pilar
    Medina, Javier
    Garicano, Fernando
    Lopez, Pedro
    Campos Balea, Begona
    Rodriguez Garzotto, Analia
    Munoz-Couselo, Eva
    ONCOTARGETS AND THERAPY, 2021, 14 : 5345 - 5352
  • [45] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Casey Quinn
    Qiufei Ma
    Amber Kudlac
    Stephen Palmer
    Beth Barber
    Zhongyun Zhao
    Advances in Therapy, 2016, 33 : 643 - 657
  • [46] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Quinn, Casey
    Ma, Qiufei
    Kudlac, Amber
    Palmer, Stephen
    Barber, Beth
    Zhao, Zhongyun
    ADVANCES IN THERAPY, 2016, 33 (04) : 643 - 657
  • [47] Vemurafenib A Guide to its Use in Unresectable or Metastatic Melanoma
    Keating, Gillian M.
    Lyseng-Williamson, Katherine A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2013, 14 (01) : 65 - 69
  • [48] Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib
    Sachpekidis, Christos
    Hassel, Jessica C.
    Dimitrakopoulou-Strauss, Antonia
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2017, 20 (03): : 251 - 253
  • [49] A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
    Harding, James J.
    Catalanotti, Federica
    Munhoz, Rodrigo R.
    Cheng, Donavan T.
    Yaqubie, Amin
    Kelly, Nicole
    Mcdermott, Gregory C.
    Kersellius, Romona
    Merghoub, Taha
    Lacouture, Mario E.
    Carvajal, Richard D.
    Panageas, Katherine S.
    Berger, Michael F.
    Rosen, Neal
    Solit, David B.
    Chapman, Paul B.
    ONCOLOGIST, 2015, 20 (07) : 789 - 797
  • [50] Vemurafenib as a therapeutic option for treatment of melanoma
    Leicht, Simon
    Wertheimer, Christian
    Liegl, Raffael
    Kampik, Anselm
    Eibl-Lindner, Kirsten
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
12345